KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cost of Revenue: 2016-2025

Historic Cost of Revenue for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Sep 2025 value amounting to $21.6 million.

  • Acadia Pharmaceuticals' Cost of Revenue rose 14.80% to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.6 million, marking a year-over-year increase of 8.53%. This contributed to the annual value of $81.8 million for FY2024, which is 96.55% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Cost of Revenue stood at $21.6 million for Q3 2025, which was up 4.40% from $20.7 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Cost of Revenue's 5-year high stood at $23.0 million during Q1 2024, with a 5-year trough of $1.7 million in Q1 2023.
  • For the 3-year period, Acadia Pharmaceuticals' Cost of Revenue averaged around $16.9 million, with its median value being $18.9 million (2024).
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Cost of Revenue plummeted by 77.54% in 2022, and later skyrocketed by 1,276.78% in 2024.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Cost of Revenue stood at $10.7 million in 2021, then plummeted by 77.54% to $2.4 million in 2022, then skyrocketed by 641.44% to $17.9 million in 2023, then increased by 21.87% to $21.8 million in 2024, then increased by 14.80% to $21.6 million in 2025.
  • Its last three reported values are $21.6 million in Q3 2025, $20.7 million for Q2 2025, and $20.4 million during Q1 2025.